


MDH-014 for the Treatment of Intractable CNS Disease

MDH-014 (*Lactobacillus paracasei* EV) is a new class of first-in-class oral therapeutic indicated for intractable CNS diseases, such as Autism spectrum disorder (ASD), Alzheimer's disease (AD), Parkinson's disease (PD), & more

MDH-014

- Naïve (natural) EVs from a single **Lactobacillus** strain



Value Propositions

1. **First-in-class:** a new modality drug with a novel mechanism of action (MoA)
2. **Very safe:** a newly discovered, safe commensal bacterium *Lactobacillus paracasei*-derived EVs
3. **Effective:** a disease-modifying therapy against intractable CNS diseases including autism spectrum disorder (ASD), Alzheimer's disease (AD), & Parkinson's disease (PD)
4. **Convenient administration:** orally-delivered
5. **Affordable:** cost effective production



MDH-014: Key Indications & Development Timeline

Key Indications

- 1) Autism spectrum disorder (ASD)**
- 2) Alzheimer's disease (AD)**
- 3) Parkinson's disease (PD)**
- 4) Amyotrophic lateral sclerosis (ALS)

Core patent

- ✓ PCT (KR2021/003075) application date at 12/Mar/2021
- ✓ Registered at KR (as of July 2022)
- ✓ Pending at US, EP, JP, & CN (as of July 2022)

Development Timeline

